Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Jan 25;15(1):e34181.
doi: 10.7759/cureus.34181. eCollection 2023 Jan.

From Temporal Cell Arteritis to Giant Cell Aortitis Presenting as a Constitutional Syndrome: A Case Report

Affiliations
Case Reports

From Temporal Cell Arteritis to Giant Cell Aortitis Presenting as a Constitutional Syndrome: A Case Report

Marta Lopes et al. Cureus. .

Abstract

Giant cell arteritis (GCA) is the most common form of systemic vasculitis in adults, especially in patients over the age of 50. It manifests most commonly with an intense headache and visual symptoms. Although constitutional symptoms are also frequent in GCA, these can be dominant in 15% of patients at first presentation and 20% of patients when relapsing. Treatment with high-dose steroids should be initiated as soon as possible to rapidly control the inflammatory symptoms and prevent ischemic complications, the most feared being blindness from anterior ischemic optic neuropathy. We present a case of a 72-year-old man who presented to the emergency department with a right temporal headache with retroocular radiation associated with scalp hyperesthesia, without any visual symptoms. The patient also reported low-grade fever, night sweats, anorexia, and weight loss over the last two months. The physical exam revealed a tortuous and indurated right superficial temporal artery, which was tender to palpation. The ophthalmological examination was normal. The erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were elevated, and he also had inflammatory anemia with a hemoglobin of 11.7 g/L. Due to this clinical presentation as well as the elevation of inflammatory markers, the diagnosis of temporal arteritis was suspected, and the patient was started on prednisolone (1 mg/kg). A right temporal artery biopsy was performed on the first week after the initiation of corticotherapy and was negative. After treatment initiation, there was a remission of symptoms accompanied by a decrease and normalization of inflammatory markers. However, after steroid tapering, there was a reappearance of constitutional symptoms but without any other organ-specific symptoms, such as headache, visual loss, arthralgia, or other. The corticosteroid dose was increased to the initial dosage, but there was no improvement in the symptoms this time. After the exclusion of other causes of the constitutional syndrome, a positron-emission tomography (PET) scan was performed, which showed a grade 2 aortitis. The diagnosis of giant cell aortitis was assumed, and given the lack of clinical response to corticotherapy, tocilizumab was initiated with a resolution of constitutional symptoms as well as a normalization of inflammatory markers. In conclusion, we report a case of temporal cell arteritis that further progressed to aortitis manifesting solely with constitutional symptoms. Furthermore, there was no optimal response to corticotherapy and no improvement with tocilizumab, therefore making this a case with a unique and infrequent clinical course. GCA is characterized by a wide variety of symptoms and organ involvement, and although it most frequently affects temporal arteries, it can be associated with aortic involvement that can cause life-threatening structural complications, highlighting the need for a high suspicion index for this condition.

Keywords: constitutional syndrome; giant cell aortitis; giant cell arteritis; large-artery vasculitis; tocilizumab.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. PET scans showing the evolution of aortitis before (yellow arrow) and after (blue arrow) treatment
The first PET scan on the right shows grade 2 aortitis (yellow arrow), which was performed before treatment with tocilizumab. The second scan was performed after tocilizumab initiation with an improvement of aortic inflammation with grade 1 aortitis (blue arrow). PET: Positron-emission tomography.
Figure 2
Figure 2. Parasternal long-axis view on transthoracic echocardiogram showing an ascending aortic dilation of 44 mm (green arrow)

References

    1. A case of giant cell arteritis presenting as catastrophic posterior circulation stroke: a diagnostic dilemma. Wong J, Chan S, Shetty A. Cureus. 2022;14:0. - PMC - PubMed
    1. A new era for giant cell arteritis. Lyons HS, Quick V, Sinclair AJ, Nagaraju S, Mollan SP. Eye (Lond) 2020;34:1013–1026. - PMC - PubMed
    1. Giant cell arteritis: 2018 review. Winkler A, True D. https://pubmed.ncbi.nlm.nih.gov/30385998/ Mo Med. 2018;115:468–470. - PMC - PubMed
    1. Isolated aortitis as an atypical presentation of giant cell arteritis. Martinez-Valle F, Ramentol-Sintes M, Perez-Bocanegra C, et al. http://dx.doi.org/10.1136/annrheumdis-2013-eular.2771 Ann Rheum Dis. 2013;72:925–926.
    1. The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Dejaco C, Duftner C, Buttgereit F, Matteson EL, Dasgupta B. Rheumatology (Oxford) 2017;56:506–515. - PubMed

Publication types

LinkOut - more resources